TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in tracheal anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan
Endpoint domain: Mortality/survival
Primary endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan
Endpoint domain: Mortality/survival
Primary endpoint: change in office blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes from baseline in morphological content of vulvar and vaginal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in protein content of vulvar and vaginal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in enzymatic content of vulvar and vaginal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in antigen content of vulvar and vaginal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference in Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Disease Activity 28 (DAS28) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving ACR20/50/70 Responses After the Third Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormal clinical hematology test findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects with abnormal clinical chemistry test findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in recession depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in the Average Daily Worst Pain Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Relative Difference in Patient Glucose Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite outcome of all-cause mortality, severe infection, severe diarrhea or fever
Endpoint domain: Mortality/survival
Primary endpoint: Total febrile or antibiotic days
Endpoint domain: Adverse events/effects
Primary endpoint: HIV Sexual Risk Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cost Effectiveness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness of neuro vision rehabilitation on vision dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gestation length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction in mean absolute VAS-pruritus score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geriatric Depression Scale Change Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State-Trait Anxiety Inventory (STAI) Change Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recruitment, retention and adherence rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Reverse Popeye Deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall hematologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Utilization and Attrition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Virologic response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SGRQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to first major bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first stroke/systemic embolism (SE) event
Endpoint domain: Adverse events/effects
Primary endpoint: Physical Fitness - VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Fitness - Distance Walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimation of pulmonary edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of mediastinal downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of keloid post scar excision
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Within-patient Percent Change From Baseline in Liver Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching Systolic BP goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Menstrual blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in patient safety attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attention and Memory Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: concentrations of cefepime and zidebactam in epithelial lining fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentrations of cefepime and zidebactam in alveolar macrophage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in gingival inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of PLX8394
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PTSD Checklist (PCL-5) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Safety Measures
Endpoint domain: Adverse events/effects
Primary endpoint: Exit-site/tunnel infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in inflammation as measured through bioimpedance analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mini Mental State Exam (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time spent on sponge and instrument counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Discrepancies and miscounts in sponge count
Endpoint domain: Adverse events/effects
Primary endpoint: Time spent searching for a missing sponge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage change in SALT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Visual Analogue Scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with diarrheal disease
Endpoint domain: Adverse events/effects
Primary endpoint: BMD Lumbar Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of hepatitis flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline Skin Conductance Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Treatment - Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: vaginal dryness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of QuantiFERON Monitor® levels (interferon gamma, UI/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Care Plans
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Major Access Site Closure-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of superselective intraarterial Cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Descriptive frequency of subjects experiencing toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Concentrations of (S)-ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentrations of Nor-(S)-ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of MF59-H1N1sw flu vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of MF59-H1N1sw flu vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of MF59-H1N1sw flu vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and toxic effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative analgesic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Reduction In Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative importance of attributes of ESA treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neuroinflammation in cortical and/or subcortical structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MA (-) urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDS clinical symptoms (mainly anemia symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrence of Barrett's esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in diagnosing ovarian masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of portal vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Burden of ESBL-colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Burden of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experience each adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: ADAS-Cog-Exec Global Composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: 7-day Point Prevalence Abstinence From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total ketamine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Modified Rankin Scale (mRS) <=3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum macrophage inhibitory cytokine-1 (MIC-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in days of inpatient hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Best Observed Radiographic Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Developed New Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of acute procedural success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of major adverse event (MAE) at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of serious adverse events (SAEs)/adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Local tolerability assessment of the vaccination site
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression-Improvement Scale (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With a Score of ≤2 on the CGI-SF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adequacy of bowel preparation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area-under-the-curve during the dosing interval (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum total plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum plasma concentration (t-max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bowel movement frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Cytomegalovirus (CMV) Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Day-by-day changes of lung mechanical impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Day-by-day changes of patient's symptom
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation coefficient between percentage of increase in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation coefficient between percentage of increase in Trabecular Fragment Length (TFL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hallucinations change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Source-monitoring ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Phonation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in the Screen IVF questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: response rate of treated tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Weight change rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Siderophilin change status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin 1 change status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin 6 change status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Necrosis Factor α change status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of invasive breast cancer events and DCIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Six month survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Reported Falls
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Short Physical Performance Battery (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCLA loneliness Scale (version 3)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lubben Social Network Scale - 6 (LSNS-6)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percentage of Participants With Detectable Talimogene Laherparepvec DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Number of Falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline In Body Mass Index At 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline In Fasting Glucose Profile At 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline In Fasting Glycated Haemoglobin At 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hydromorphone consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Problems faced at work due to IA
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patients needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Motivations to continue working
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Strategies helpful for maintaining employment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Disease status biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic total exposure to aXa (AUC0-τ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma aXa-Profile: Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma aXa-Profile: C0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of midazolam, caffeine, and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of midazolam, caffeine, and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of CMV reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of EBV reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Vitamin D levels in pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reinfection rates of STHs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline on the WURSS-44
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitude towards learning professional ethics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Illness Management and Recovery Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Illness Management and Recovery Treatment Integrity Scale
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Laboratory Confirmed Influenza
Endpoint domain: Adverse events/effects
Primary endpoint: Total long chain PUFA in erythrocyte membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma long chain n-3 polyunsaturated fatty acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of parastomal hernia after 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in B type ultrasonography index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Ocular comfort/tolerability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-∞ of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular Function Using Microperimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular Function Using Multi-focal ERG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in transaminases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: EP's incidence
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of thyroid hormone autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Functional mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Global scores of Symptom-Checklist 90 (SCL-90)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: white matter microstructure integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Specificity of the two diagnostic strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-12(DHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24(PQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes